Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors

[1]  C. Su,et al.  Current landscape and perspective of oncolytic viruses and their combination therapies , 2022, Translational oncology.

[2]  Yihong Peng,et al.  Long-Term Infection and Pathogenesis in a Novel Mouse Model of Human Respiratory Syncytial Virus , 2022, Viruses.

[3]  Franco J. Vizeacoumar,et al.  DDX41 is required for cGAS-STING activation against DNA virus infection , 2022, Cell reports.

[4]  Xiangxi Wang,et al.  Atomic Structures of Coxsackievirus B5 Provide Key Information on Viral Evolution and Survival , 2022, Journal of virology.

[5]  M. Lawson,et al.  The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma , 2021, Cancers.

[6]  Juli Bai,et al.  Nuclear cGAS: sequestration and beyond , 2021, Protein & Cell.

[7]  Yang Yang,et al.  STING1 is essential for an RNA-virus triggered autophagy , 2021, Autophagy.

[8]  H. Fechner,et al.  Coxsackievirus B3—Its Potential as an Oncolytic Virus , 2021, Viruses.

[9]  Yingying Lin,et al.  Stigmasterol Simultaneously Induces Apoptosis and Protective Autophagy by Inhibiting Akt/mTOR Pathway in Gastric Cancer Cells , 2021, Frontiers in Oncology.

[10]  M. Lotze,et al.  In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy , 2021, Frontiers in Immunology.

[11]  Ning Li,et al.  The Landscape of Cell and Gene Therapies for Solid Tumors. , 2021, Cancer cell.

[12]  Caicun Zhou,et al.  Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[13]  A. Allegra,et al.  Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs , 2020, Current oncology.

[14]  Hongyun Wang,et al.  Nuclear cGAS Functions Non-canonically to Enhance Antiviral Immunity via Recruiting Methyltransferase Prmt5. , 2020, Cell reports.

[15]  G. Brewer,et al.  IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex , 2020, Nature Communications.

[16]  Zhiyi Liu,et al.  Novel recombinant coxsackievirus B3 with genetically inserted basic peptide elicits robust antitumor activity against lung cancer , 2020, Cancer medicine.

[17]  J. Schlom,et al.  The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa , 2020, Frontiers in Oncology.

[18]  N. Jayawardena,et al.  Virus–Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development , 2020, Oncolytic virotherapy.

[19]  B. Mishra,et al.  Foot-and-mouth disease virus induces PERK mediated autophagy to suppress antiviral interferon response. , 2020, Journal of cell science.

[20]  M. O’Connor,et al.  Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically , 2019, Molecular Cancer Therapeutics.

[21]  Honglin Luo,et al.  Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma , 2019, Molecular therapy oncolytics.

[22]  T. Natsume,et al.  Intrinsically Disordered Protein TEX264 Mediates ER-phagy. , 2019, Molecular cell.

[23]  N. Manel,et al.  The N-Terminal Domain of cGAS Determines Preferential Association with Centromeric DNA and Innate Immune Activation in the Nucleus , 2019, Cell reports.

[24]  Zhenglun Liang,et al.  A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5 , 2018, Emerging Microbes & Infections.

[25]  M. Rasti,et al.  An update on enterovirus 71 infection and interferon type I response , 2018, Reviews in medical virology.

[26]  Xiao Xiao,et al.  DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage , 2018, Nature Communications.

[27]  M. Coffey,et al.  Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy , 2018, Cancer Immunology Research.

[28]  Q. Ding,et al.  Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease , 2018, Proceedings of the National Academy of Sciences.

[29]  E. Passegué,et al.  Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging , 2018, Science.

[30]  Wei Wang,et al.  Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population , 2018, Emerging Microbes & Infections.

[31]  Astrid Zimmermann,et al.  Overcoming hypoxia-induced tumor radioresistance in non-small cell lung cancer by targeting DNA-dependent protein kinase in combination with carbon ion irradiation , 2017, Radiation Oncology.

[32]  Liwu Fu,et al.  Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma , 2017, Science Translational Medicine.

[33]  Ying-Jan Wang,et al.  A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer. , 2017, Cancer letters.

[34]  X. Tan,et al.  Selective Antagonism of Bcl-xL Potentiates M1 Oncolysis by Enhancing Mitochondrial Apoptosis. , 2017, Human gene therapy.

[35]  Wenqing Gao,et al.  Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin , 2017, Nature.

[36]  Patricia A Corrigan,et al.  Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma , 2017, The Annals of pharmacotherapy.

[37]  Tingzhe Sun,et al.  Modeling amplified p53 responses under DNA-PK inhibition in DNA damage response , 2017, Oncotarget.

[38]  C. Zheng,et al.  RIG-I-Mediated STING Upregulation Restricts Herpes Simplex Virus 1 Infection , 2016, Journal of Virology.

[39]  N. Chapman,et al.  Reversion to wildtype of a mutated and nonfunctional coxsackievirus B3CRE(2C). , 2016, Virus research.

[40]  Jiong Cai,et al.  A classical PKA inhibitor increases the oncolytic effect of M1 virus via activation of exchange protein directly activated by cAMP 1 , 2016, Oncotarget.

[41]  Zhenglun Liang,et al.  An epidemic of coxsackievirus B3 infection in infants and children in Jiangsu Province, China: a prospective cohort study , 2016, Archives of Virology.

[42]  A. Zambrano,et al.  Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus , 2016, Virulence.

[43]  Pēteris Alberts,et al.  Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study , 2015, Melanoma research.

[44]  H. Kaufman,et al.  Oncolytic viruses: a new class of immunotherapy drugs , 2015, Nature Reviews Drug Discovery.

[45]  E. Colvin,et al.  A historical perspective of pancreatic cancer mouse models. , 2014, Seminars in cell & developmental biology.

[46]  C. Rice,et al.  IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage , 2013, The EMBO journal.

[47]  E. B. Butler,et al.  Identification and characterization of a small inhibitory peptide that can target DNA-PKcs autophosphorylation and increase tumor radiosensitivity. , 2012, International journal of radiation oncology, biology, physics.

[48]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[49]  Y. Zou,et al.  DNA-PK, ATM and ATR collaboratively regulate p53-RPA interaction to facilitate homologous recombination DNA repair , 2012, Oncogene.

[50]  Y. Nakanishi,et al.  Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. , 2012, Cancer research.

[51]  C. Hetz.  The unfolded protein response: controlling cell fate decisions under ER stress and beyond , 2012, Nature Reviews Molecular Cell Biology.

[52]  G. Sen,et al.  High-Throughput Screening for TLR3–IFN Regulatory Factor 3 Signaling Pathway Modulators Identifies Several Antipsychotic Drugs as TLR Inhibitors , 2010, The Journal of Immunology.

[53]  R. Guerra-Sá,et al.  Coxsackievirus B5 induced apoptosis of HeLa cells: effects on p53 and SUMO. , 2010, Virology.

[54]  Jesse D. Martinez,et al.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.

[55]  Seung-Yong Yoon,et al.  Primary neurons become less susceptible to coxsackievirus B5 following maturation: The correlation with the decreased level of CAR expression on cell surface , 2008, Journal of medical virology.

[56]  L. Salford,et al.  Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers , 2006, Journal of Molecular Histology.

[57]  M. Lai,et al.  Hepatitis C Virus Triggers Mitochondrial Permeability Transition with Production of Reactive Oxygen Species, Leading to DNA Damage and STAT3 Activation , 2006, Journal of Virology.

[58]  B. He.  Viruses, endoplasmic reticulum stress, and interferon responses , 2006, Cell Death and Differentiation.

[59]  B. Murphy,et al.  Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression. , 2005, Journal of virological methods.

[60]  B. Hering,et al.  Prevalent human coxsackie B‐5 virus infects porcine islet cells primarily using the coxsackie‐adenovirus receptor , 2004, Xenotransplantation.

[61]  T. Golub,et al.  mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.

[62]  P. Hersey,et al.  Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21 , 2004, Clinical Cancer Research.

[63]  Li Yang,et al.  LY294002 and Rapamycin promote coxsackievirus-induced cytopathic effect and apoptosis via inhibition of PI3K/AKT/mTOR signaling pathway , 2013, Molecular and Cellular Biochemistry.

[64]  N. Curtin,et al.  DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin , 2013, Breast Cancer Research and Treatment.

[65]  V. Preedy,et al.  Prospective Cohort Study , 2010 .